GSK Starts Phase 3 Program to Evaluate Retosiban For Preterm Births
March 17 2015 - 7:43AM
Dow Jones News
LONDON--GlaxoSmithKline PLC (GSK) said it started a late-stage
trial of retosiban, a drug that could potentially be used to
improve the prospects for babies that are born before term.
The phase three program will seek to measure whether the
treatment delays the onset of a baby's delivery and whether it
improves the mortality rate. A follow-up study will assess the
long-term consequences for infants.
Shares at 1110 GMT traded seven pence or 0.4% higher at 1,584
pence.
Write to Ed Ballard at ed.ballard@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
